Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
作者信息
Chadwick Christopher, Friede Martin, Moen Ann, Nannei Claudia, Sparrow Erin
机构信息
The World Health Organization, Geneva, Switzerland.
The World Health Organization, Geneva, Switzerland.
出版信息
Vaccine. 2022 Aug 5;40(33):4673-4675. doi: 10.1016/j.vaccine.2022.06.057. Epub 2022 Jul 7.
Abstract
摘要
相似文献
1
Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.
Vaccine. 2022 Aug 5;40(33):4673-4675. doi: 10.1016/j.vaccine.2022.06.057. Epub 2022 Jul 7.
2
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.
3
A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).
Vaccine. 2016 Oct 26;34(45):5414-5419. doi: 10.1016/j.vaccine.2016.07.025. Epub 2016 Aug 3.
4
Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
Curr Opin Pharmacol. 2007 Oct;7(5):484-90. doi: 10.1016/j.coph.2007.06.004. Epub 2007 Jul 17.
5
Designing vaccines for pandemic influenza.
Curr Top Microbiol Immunol. 2009;333:165-76. doi: 10.1007/978-3-540-92165-3_8.
6
Avian influenza vaccines against H5N1 'bird flu'.
Trends Biotechnol. 2014 Mar;32(3):147-56. doi: 10.1016/j.tibtech.2014.01.001. Epub 2014 Feb 1.
7
Recommended composition of influenza virus vaccines for use in the 2007-2008 influenza season.
Wkly Epidemiol Rec. 2007 Mar 2;82(9):69-74.
8
Strategies for developing vaccines against H5N1 influenza A viruses.
Trends Mol Med. 2006 Nov;12(11):506-14. doi: 10.1016/j.molmed.2006.09.003. Epub 2006 Sep 29.
9
Development of live-attenuated influenza vaccines against outbreaks of H5N1 influenza.
Viruses. 2012 Dec 10;4(12):3589-605. doi: 10.3390/v4123589.
10
Recommended composition of influenza virus vaccines for use in the 2008 influenza season.
Wkly Epidemiol Rec. 2007 Oct 5;82(40):351-6.
引用本文的文献
1
Global production capacity of seasonal and pandemic influenza vaccines in 2023.
Vaccine. 2025 Apr 2;51:126839. doi: 10.1016/j.vaccine.2025.126839. Epub 2025 Feb 18.
2
'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.
PLOS Glob Public Health. 2024 Sep 23;4(9):e0003173. doi: 10.1371/journal.pgph.0003173. eCollection 2024.
3
Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries.
PLOS Glob Public Health. 2024 Jul 1;4(7):e0003418. doi: 10.1371/journal.pgph.0003418. eCollection 2024.
4
Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond.
Pharmaceut Med. 2023 May;37(3):203-214. doi: 10.1007/s40290-023-00473-z. Epub 2023 Apr 28.
本文引用的文献
1
Global production capacity of seasonal and pandemic influenza vaccines in 2019.
Vaccine. 2021 Jan 15;39(3):512-520. doi: 10.1016/j.vaccine.2020.12.018. Epub 2020 Dec 16.
2
Considerations for sustainable influenza vaccine production in developing countries.
Vaccine. 2016 Oct 26;34(45):5425-5429. doi: 10.1016/j.vaccine.2016.08.056. Epub 2016 Sep 7.
3
Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative.
Vaccine. 2016 Oct 26;34(45):5420-5424. doi: 10.1016/j.vaccine.2016.07.047. Epub 2016 Aug 6.
4
Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.
Vaccine. 2016 Oct 26;34(45):5430-5435. doi: 10.1016/j.vaccine.2016.07.046. Epub 2016 Jul 30.
5
Comprehensive hands-on training for influenza vaccine manufacturing: a WHO-BARDA-BTEC partnership for global workforce development.
Biochem Mol Biol Educ. 2014 Sep-Oct;42(5):414-9. doi: 10.1002/bmb.20817. Epub 2014 Aug 18.
6
Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program.
Vaccine. 2013 Mar 15;31(12):1646-9. doi: 10.1016/j.vaccine.2012.06.041. Epub 2012 Jun 29.
7
An international technology platform for influenza vaccines.
Vaccine. 2011 Jul 1;29 Suppl 1:A8-11. doi: 10.1016/j.vaccine.2011.04.124.
8
The Vaccine Formulation Laboratory: a platform for access to adjuvants.
Vaccine. 2011 Jul 1;29 Suppl 1:A37-9. doi: 10.1016/j.vaccine.2011.04.125.
9
WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.
Vaccine. 2011 Jul 1;29 Suppl 1:A2-7. doi: 10.1016/j.vaccine.2011.02.079.
Zotero 插件